{"entity":{"id":"tbi-1501","kind":"drug","name":"TBI-1501","aka":[],"tldr":"TBI-1501 is an experimental CAR-T cell therapy from Takara Bio in phase 2 trials for acute lymphoblastic leukaemia, aimed at CD19.","summary":"TBI-1501 is a CAR-T cell therapy developed by Takara Bio. Its target is CD19. ClinicalTrials.gov describes the intervention as: Phase-I portion: Cyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells, (cohort -1: 3×10\\^5 cells/kg, cohort 1: 1×10\\^6 cells/kg, cohort 2: 3×10\\^6 cells/kg). Phase-II portion: Recommended dose of. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in acute lymphoblastic leukaemia. The largest, NCT03155191, plans to enrol 21 participants with primary completion expected 2035-03-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of TBI-1501","url":"https://clinicaltrials.gov/search?intr=TBI-1501"},{"label":"Sponsor page","url":"https://www.takara-bio.com"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":["cd19"],"drugs":[],"companies":["takara-bio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct03155191"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"CAR-T cell therapy","mechanism":"CAR-T cell therapy directed at CD19, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tbi-1501/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"takara-bio","kind":"company","name":"Takara Bio","route":"/companies/takara-bio/"}],"trial":[{"id":"nct03155191","kind":"trial","name":"Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia","route":"/trials/nct03155191/"}]}}